• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi appoints new Directors of Research & Development and Strategy & Operations

Home > News

DNDi appoints new Directors of Research & Development and Strategy & Operations

Portraits of Laurent Fraisse and Rudi Paye
25 Oct 2019

Dr Laurent Fraisse and Mr Rudi Paye join DNDi’s Executive Management Team

DNDi is very pleased to announce the appointments of Dr Laurent Fraisse as Research & Development Director, and Mr Rudi Paye as Strategy and Operations Director.

Dr Fraisse comes to DNDi with substantial experience in the field of infectious diseases. Most recently, he worked as the Global Head of Infectious Disease R&D at Evotec. He was also Chair of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Strategic Governing Group dedicated to infectious diseases.

Prior to his time at Evotec, Dr Fraisse was Head of the Infectious Diseases Therapeutic Unit and R&D Head for Infectious Diseases at Sanofi. Dr Fraisse was also responsible for research projects within Elf Atochem and Sanofi. Dr Fraisse graduated from the Ecole Nationale Supérieure d’Agronomie in Rennes, France. He obtained his PhD in Biotechnology at the Institut National Polytechnique in Toulouse in 1993.

Mr Paye joins DNDi after 19 years in the pharmaceutical and animal health industries of Merial/Sanofi and Boehringer-Ingelheim, where he occupied various leadership roles in industrial operations finance, corporate finance, business development, and alliance management.

Prior to these assignments, Mr Paye worked within the risk management function of a major glass manufacturer, and then as ERP/Finance Management Consultant at PriceWaterhouseCoopers. Mr Paye completed his MBA at ICHEC Brussels Business School.

“It is with enormous pleasure that we welcome both Laurent and Rudi to DNDi,” said Dr Bernard Pécoul, Executive Director, DNDi. “Their impressive track records and wealth of experience will be a great asset to us as we continue to strengthen our project portfolio and advance the discovery and development of new treatments for neglected patients.”

Read, watch, share

Loading...
Statements
19 May 2026

DNDi interventions at the 79th World Health Assembly

Dr Sergio Sosa-Estani
Statements
15 May 2026

DNDi statement on hantavirus outbreak: ‘Investment in pandemic preparedness efforts remains insufficient.’

Statements
13 May 2026

DNDi’s briefing note for 79th World Health Assembly

Close up of legs with sandals on a dry soil
Press releases
12 May 2026

DNDi welcomes GHIT support for global evaluation and registration of fosravuconazole for eumycetoma, in collaboration with Eisai

Press releases
27 Apr 2026

Thailand registers ravidasvir, a simple-to-use and effective antiviral for hepatitis C, expanding treatment options for Thai patients

Stories

Lab lessons that matter: Pharmacy students help bridge the gap in research for neglected diseases

News
31 Mar 2026

DNDi is looking for a Board Treasurer to join its Board of Directors

Title copy on white and orange background, picture of Fr Robinson on the right hand
Videos
26 Mar 2026

Manufacturing medicines for NTDs, with Dr Stephen Robinson

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license